MaterniT21 Plus Test Adoption Drives Sequenom Q2 Revenues up 38 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Sequenom announced after the close of the market on Thursday that revenues spiked 38 percent year over year during the second quarter as the MaterniT21 Plus fetal aneuploidy test continued to see strong adoption.

For the period ended June 30, total revenues came in at $18.3 million, compared to $13.3 million a year ago, but missed the consensus analyst estimate of $19.2 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.